( behavior. These endpoints were the Alzh...)Medivation Announces Presentation of New Subset Analyses From,Dimebon Phase 2 Alzheimer's Disease Trial at American Academy of,Neurology Annual Meeting,Health

behavior. These endpoints were the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), the Clinician's Interview-Based Impression of Change with a caregiver interview (CIBIC-plus), the Alzheimer's Disease Cooperative Study Group-Activities of Daily Living (ADCS-ADL), the Neuropsychiatric Inventory (NPI) and the Mini Mental State Exam (MMSE), the first two of which have been used by the U.S. Food and Drug Administration to register all drugs previously approved to treat mild-to-moderate Alzheimer's disease. The study was conducted at multiple sites in Russia. Patients received oral Dimebon, 20 mg three times a day (60 mg/day), or placebo.

Previously announced results from the six-month study showed that, overall, Dimebon-treated patients demonstrated significant improvement versus placebo on the primary endpoint of ADAS-cog (p<0.0001) and the key secondary endpoint of CIBIC-plus (p<0.0001). Dimebon-treated patients also significantly outperformed the placebo-treated patients (p<0.01) on the three additional secondary endpoints: the ADCS-ADL, the NPI and the MMSE.

Dimebon was well tolerated in this study. Dry mouth, which occurred in 13.5 percent of Dimebon-treated patients, was the only gastrointestinal side effect that occurred with an incidence higher than three percent. Fewer Dimebon-treated patients experienced serious adverse events than placebo- treated patients (2.2 percent versus 7.4 percent, respectively). A higher percentage of Dimebon-treated patients than placebo-treated patients completed the trial (87.6 percent and 81.9 percent, respectively), for an overall trial completion rate of 84.7 percent.

Teleconference/Webcast Details

Medivation will hold a teleconference tomorrow, Friday, May 4, at 9:00 a.m. Eastern time with Dr. Hung, Dr. Seely and Dr. Doody to discuss the data and answer questions. To participate in the live call by telephone, please dial 800-289-0485 from the U.S. or 913-981-5518 internationally.
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Medivation Announces First U.S. Presentation of Data From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Medivation Announces Presentation of Full Top-Line Data From Dimebon Six-Month Trial at Major International Alzheimers Disease Conference
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone